Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset RVTY

Coverage 92,717 Raw stories ingested 8,002 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,728 Assets with fetched stories

Cryptocurrencies BTC 4,284 ETH 3,097 SOL 1,755 XRP 1,707 USDC 969 HYPE 835

Stocks SPCX 882 MU 724 NVDA 694 MSFT 564 GOOGL 538 TSLA 506

Commodities GOLD 159 SILVER 93 OIL 51 PLATINUM 5 PALLADIUM 2 COPPER 1

Forex EURUSD 148 GBPUSD 143 USDCAD 51 USDJPY 37 AUDUSD 33 NZDUSD 23

1,682 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 58s ago
FMP Forex News Fetch every 5 min 4m ago
CoinGecko News Fetch every 5 min 4m ago
FIO Stock News Fetch every 10 min 8m ago
Patria Stock News Fetch every 10 min 8m ago
Editorial rewrite Rewrite every minute 58s ago
Asset sync Assets every 1 hour 48m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-07-24 17:37 2d ago Published 2026-07-24 12:05 2d ago	Revvity vyvíjí platformu pro hromadné testování tuberkulózy Revvity vyvíjí T-SPOT A201 pro vysoce objemné testování latentní tuberkulózy; platforma má zvládnout až 384 vzorků za osm hodin. Akcie RVTY po oznámení přidaly 2,4 %. RVTY Revvity	FMP Stock News	78
Original source text Key Takeaways Revvity is developing T-SPOT A201 for high-volume latent TB testing, targeting a late-2027 launch.The platform can process up to 384 samples in eight hours with 45 seconds of hands-on time per sample.RVTY shares rose 2.4% after the announcement and gained 16.9% year to date, beating key benchmarks. Revvity, Inc. (RVTY - Free Report) recently announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support large-volume clinical laboratories performing latent tuberculosis (TB) testing. Targeted for launch in the second half of 2027, the platform is engineered to deliver the performance advantages of the T-SPOT.TB assay while enabling greater workflow efficiency and scalability for high-throughput testing environments. Per management, the T-SPOT A201 automation platform marks a significant advancement in expanding access to the benefits of T-SPOT.TB testing for high-volume laboratories. The company believes the solution will provide the performance, workflow efficiency and competitive economics needed by high-volume clinical labs, reinforcing its commitment to delivering scalable automation technologies for infectious disease diagnostics. Likely Trend of RVTY Stock Following the NewsFollowing the announcement, RVTY shares gained 2.4% at yesterday’s close. Year to date, the stock rose 16.9%, outperforming the industry’s 1.8% decline and the S&P 500’s 7.4% gain. The development of the T-SPOT A201 platform is expected to strengthen Revvity’s infectious disease diagnostics and laboratory automation portfolio. By addressing the growing need for high-throughput latent TB testing, the company can enhance its position among large clinical laboratories while expanding opportunities within public health and diagnostic markets. Upon successful commercialization, the platform could drive broader adoption of Revvity’s automation solutions, support long-term customer relationships and contribute to sustained revenue growth. RVTY currently has a market capitalization of $12.33 billion. Image Source: Zacks Investment Research More on the NewsThe T-SPOT A201 expands Revvity’s portfolio of automation solutions that simplify the T-SPOT.TB workflow without compromising clinical performance. The company already offers the FDA-approved and CE-IVD-marked Auto-Pure 2400 liquid handler for laboratories with lower testing volumes. Designed to process up to 24 samples per run, the Auto-Pure 2400 completes first-day T-SPOT.TB workflows in less than 3.5 hours with minimal user interaction while delivering low indeterminate results, high sensitivity and specificity, extended sample stability and efficient sample handling. These capabilities enable laboratories of different sizes to improve workflow efficiency while maintaining confidence in latent TB test results. Built on the success of the Auto-Pure 2400 liquid handling platform, the T-SPOT A201 is designed to process up to 384 samples per instrument during an eight-hour shift while requiring only 45 seconds of hands-on time per sample. The platform is expected to help laboratories manage rising testing volumes driven by immigration screening, pre-treatment evaluations for immunosuppressive therapies and broader public health initiatives, while supporting timely and accurate latent TB detection. Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the U.S. tuberculosis diagnostics market is predicted to be valued at $607.5 million in 2026 and is expected to witness a CAGR of 5.3% through 2035. Factors like the increasing adoption of rapid molecular and nucleic acid amplification tests, growing focus on detection of latent and drug-resistant tuberculosis, rising emphasis on automation, digital reporting and laboratory workflow efficiency and continued reliance on government funding and public health laboratory networks for TB testing programs are boosting the market’s growth. Other NewsRevvity recently announced the launch of Signals for Startups, a new program to help early-stage biotechnology companies establish scalable digital informatics capabilities from the earliest stages of research. It is scheduled to launch across the United States, Europe, the Middle East and the Africa region in late July 2026. Revvity announced that its Signals Software business has been added to Anthropic’s directory for Model Context Protocol connectors, extending the capabilities of Signals AI beyond the Signals One platform. Through the integration, scientists can access Signals AI and connected R&D knowledge using Claude, including Claude Science, Anthropic’s AI workbench for scientific research. RVTY’s Zacks Rank & Key PicksRevvity currently carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , McKesson (MCK - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%. West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%. McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%. McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%. Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%. Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
	Saved 2026-07-22 17:33 4d ago Published 2026-07-22 12:05 4d ago	Revvity spustí program Signals pro startupy Revvity spustí v USA a EMEA na konci července 2026 program Signals for Startups pro rané biotechnologické firmy. Nabídne škálovatelný software, onboarding a licence pro startupy. RVTY Revvity	FMP Stock News	78
Original source text Key Takeaways Revvity will launch Signals for Startups in the United States and EMEA in late July 2026.The program offers scalable software, guided onboarding and startup-friendly licensing.It unifies research data, reduces rework and supports investor readiness and long-term growth. Revvity, Inc. (RVTY - Free Report) recently announced the launch of Signals for Startups, a new program to help early-stage biotechnology companies establish scalable digital informatics capabilities from the earliest stages of research. It is scheduled to launch across the United States, Europe, the Middle East and the Africa region in late July 2026. The program provides startup biotechs with enterprise-grade Signals software, guided onboarding, startup-friendly licensing and best-practice configurations tailored to their needs. By enabling startups to adopt robust informatics capabilities from day one, the program aims to accelerate scientific innovation and research productivity, and reduce the time required to generate value from R&D investments. Per management, Signals for Startups is built to help emerging biotech companies to grow fast without being held back by fragmented data or workflow challenges that limit their ability to scale. The combination of startup-friendly access, guided onboarding and scalable Signals workflows enables early-stage teams to establish a solid digital foundation, accelerate discovery and prepare for investor readiness and future growth. Likely Trend of RVTY Stock Following the NewsShares of RVTY have risen 3.8% since the announcement on Monday. Year to date, the stock has gained 14.2% against the industry’s 2.2% fall. However, the S&P 500 has risen 9.5% in the same timeframe. Revvity’s Signals for Startups program is expected to strengthen its software business by capturing emerging biotech companies early in their lifecycle. As these startups expand, the company can benefit from higher customer retention and increased adoption of its broader Signals portfolio. The initiative also enhances its competitive position in scientific informatics, broadens its presence in the fast-growing biotech sector and creates opportunities for sustained revenue growth through long-term customer relationships. RVTY currently has a market capitalization of $11.87 billion. Image Source: Zacks Investment Research More on the NewsEmerging biotech companies often face the challenge of managing complex research data while operating with limited IT, informatics and operational resources. Signals for Startups addresses these challenges by offering a ready-to-use, scalable informatics environment that allows scientists to focus on innovation rather than system setup. With built-in workflows for both small- and large-molecule research, the platform helps standardize data management, streamline collaboration and create a strong digital foundation from the outset. The program also provides startups with an easy entry into the Revvity Signals ecosystem through bundled software licenses suited to early-stage organizations, while offering the flexibility to expand as the business grows through funding rounds and commercialization. By replacing disconnected tools and fragmented data management with a unified informatics platform, Signals for Startups helps companies reduce inefficiencies, minimize rework and support long-term research scalability. The program builds on the broader capabilities of Revvity Signals Software, a comprehensive cloud-based scientific informatics platform that supports research from early discovery through later-stage development. Designed to promote multidisciplinary collaboration, Signals helps research teams centralize scientific data, optimize R&D workflows and accelerate innovation across pharmaceutical, biotechnology, clinical and specialty chemical applications. Trusted by over one million users worldwide, with a 97% renewal rate and used by all of the world's top 20 biopharma companies, Revvity Signals has established itself as a trusted scientific software platform. Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the life science software market is predicted to be valued at $19.65 billion in 2026 and is expected to witness a CAGR of 10.7% through 2035. Factors like the high investment in drug development and R&D by biotechnology and pharmaceutical companies to manage complex data, the need for integrated and compliant digital solutions, and urgent demand for AI-based automation in drug discovery and clinical trials to decrease time-to-market and R&D costs are boosting the market’s growth. Other NewsRevvity recently announced that its Signals Software business has been added to Anthropic’s directory for Model Context Protocol connectors, extending the capabilities of Signals AI beyond the Signals One platform. Through the integration, scientists can access Signals AI and connected R&D knowledge using Claude, including Claude Science, Anthropic’s AI workbench for scientific research. RVTY’s Zacks Rank & Key PicksRevvity currently carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) . West Pharmaceutical, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here. West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%. Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%. Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%. Cardinal Health, currently carrying a Zacks Rank #2, reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%. Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
	Saved 2026-07-01 13:01 25d ago Published 2026-07-01 08:00 25d ago	Revvity propojuje Signals AI s Claude Revvity Signals Software byl přidán do adresáře Anthropic pro MCP konektory, takže vědci mohou přes Claude přistupovat k schopnostem Signals AI a propojeným znalostem z výzkumu a vývoje, včetně Claude Science. Integrace rozšiřuje Signals AI mimo platformu Signals One a doplňuje nedávno spuštěný Signals AI native agentic framework, který je vložen napříč platformou Signals One. RVTY Revvity	FMP Stock News	78
Original source text WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude, including Claude Science, Anthropic’s new AI workbench for scientific research. As organizations increasingly adopt artificial intelligence to accelerate scientific research, the challenge is ensuring AI models have access to trusted scientific data, context and knowledge. Through the Signals MCP connector, Claude can securely access information through Signals' intelligence layer, helping researchers search, understand and act on complex R&D data using natural language. "Signals AI was designed to help scientists transform connected R&D data into understanding, decisions and action," said Kevin Willoe, president of Revvity Signals Software. "By joining Anthropic's MCP ecosystem, we're extending the reach of our Signals AI beyond our Signals One platform and enabling researchers to combine Claude's reasoning capabilities with the governed data, ontology-driven scientific context and trusted knowledge managed across the entire Revvity Signals offering." The integration complements the recently launched Signals AI native agentic framework, which embeds AI capabilities across the Signals One™ platform. Signals AI brings leading large language model (LLM) capabilities directly into the Signals platform, while the Signals MCP connector enables scientists who choose to work in Claude to securely access their connected R&D data and scientific context from Signals. By connecting Claude to the Revvity Signals platform, scientists can access organizational knowledge, experimental data and scientific context through natural language interactions while maintaining traceability and scientific precision. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries. Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.